Eltrombopag-related liver problems in immune thrombocytopenia
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
NA · Sohag University · NCT07093606
See if eltrombopag leads to liver dysfunction in adults with immune thrombocytopenia (ITP).
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Sohag University (other) |
| Locations | 1 site (Sohag) |
| Trial ID | NCT07093606 on ClinicalTrials.gov |
What this trial studies
This interventional study follows adults with primary ITP who are receiving eltrombopag and have normal baseline liver tests to measure new liver dysfunction. Participants will undergo regular liver function testing during treatment to record the incidence and severity of abnormalities. People with pre-existing liver disease or on other hepatotoxic drugs are excluded, and patients lost to follow-up are removed from analysis. The study will collect and report frequency and severity of LFT changes at Sohag University Hospital to inform safer use of eltrombopag.
Who should consider this trial
Good fit: Adults (≥18) with primary ITP who are receiving eltrombopag, have normal baseline liver function tests, and can attend regular follow-up at the study site.
Not a fit: Patients with pre-existing liver disease, those taking other hepatotoxic medications, pediatric patients, or anyone unable to complete follow-up are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, the results could help clinicians detect and manage liver side effects of eltrombopag and improve patient safety.
How similar studies have performed: Previous reports have documented liver enzyme elevations with eltrombopag, but estimates of how often and how severe these events are vary between studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver Exclusion Criteria: Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.
Where this trial is running
Sohag
- Sohag university hospital — Sohag, Egypt (RECRUITING)
Study contacts
- Study coordinator: Peter A Alfy, Resident
- Email: peter.adel.dola@gmail.com
- Phone: 01274069691
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: ITP - Immune Thrombocytopenia